Mark Newcomer Sells 61,000 Shares of Paysign, Inc. (NASDAQ:PAYS) Stock

Paysign, Inc. (NASDAQ:PAYS) CEO Mark Newcomer sold 61,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $2.89, for a total value of $176,290.00. Following the completion of the sale, the chief executive officer now directly owns 9,075,886 shares of the company’s stock, valued at $26,229,310.54. The trade was a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Mark Newcomer also recently made the following trade(s):

• On Thursday, January 23rd, Mark Newcomer sold 12,000 shares of Paysign stock. The stock was sold at an average price of $2.85, for a total transaction of $34,200.00.
• On Monday, December 9th, Mark Newcomer sold 41,000 shares of Paysign stock. The shares were sold at an average price of $3.31, for a total transaction of $135,710.00.
• On Wednesday, November 20th, Mark Newcomer sold 25,000 shares of Paysign stock. The shares were sold at an average price of $3.27, for a total transaction of $81,750.00.
• On Monday, November 18th, Mark Newcomer sold 40,000 shares of Paysign stock. The stock was sold at an average price of $3.24, for a total value of $129,600.00.

Paysign Price Performance

Shares of PAYS opened at $2.87 on Friday. The firm has a market cap of $153.69 million, a PE ratio of 19.13 and a beta of 0.95. Paysign, Inc. has a 1 year low of $2.70 and a 1 year high of $5.59. The stock’s fifty day moving average price is $3.14 and its two-hundred day moving average price is $3.90.

Paysign (NASDAQ:PAYS) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of $0.01 by $0.02. The business had revenue of $15.26 million for the quarter, compared to the consensus estimate of $14.96 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. During the same period in the prior year, the firm earned $0.02 earnings per share. Sell-side analysts anticipate that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in shares of Paysign by 25.0% during the second quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock worth $6,484,000 after acquiring an additional 301,000 shares in the last quarter. Royce & Associates LP purchased a new stake in Paysign during the 3rd quarter worth about $814,000. Barclays PLC boosted its stake in Paysign by 327.4% in the 3rd quarter. Barclays PLC now owns 47,090 shares of the company’s stock worth $173,000 after purchasing an additional 36,071 shares during the period. Rhumbline Advisers grew its holdings in Paysign by 25.1% during the 2nd quarter. Rhumbline Advisers now owns 35,835 shares of the company’s stock valued at $154,000 after buying an additional 7,190 shares in the last quarter. Finally, Joule Financial LLC bought a new stake in shares of Paysign during the third quarter valued at about $1,478,000. 25.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PAYS has been the topic of a number of recent analyst reports. Barrington Research reiterated an “outperform” rating and set a $7.00 price target on shares of Paysign in a report on Monday, November 4th. Lake Street Capital began coverage on shares of Paysign in a research report on Friday, December 20th. They set a “buy” rating and a $6.00 price target for the company.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.